These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 28969696)
1. Efficacy of rabies vaccines in dogs and cats and protection in a mouse model against European bat lyssavirus type 2. Nokireki T; Jakava-Viljanen M; Virtala AM; Sihvonen L Acta Vet Scand; 2017 Oct; 59(1):64. PubMed ID: 28969696 [TBL] [Abstract][Full Text] [Related]
2. Cross reactive antigenicity in orally vaccinated foxes and raccoon dogs against European Bat Lyssavirus type 1 and 2. Müller T; Selhorst T; Burow J; Schameitat A; Vos A Dev Biol (Basel); 2006; 125():195-204. PubMed ID: 16878477 [TBL] [Abstract][Full Text] [Related]
3. Ability of rabies vaccine strains to elicit cross-neutralising antibodies. Brookes SM; Healy DM; Fooks AR Dev Biol (Basel); 2006; 125():185-93. PubMed ID: 16878476 [TBL] [Abstract][Full Text] [Related]
4. Cross-Protection of Inactivated Rabies Vaccines for Veterinary Use against Bat Lyssaviruses Occurring in Europe. Servat A; Wasniewski M; Cliquet F Viruses; 2019 Oct; 11(10):. PubMed ID: 31614675 [TBL] [Abstract][Full Text] [Related]
5. Cross-neutralization of antibodies induced by vaccination with Purified Chick Embryo Cell Vaccine (PCECV) against different Lyssavirus species. Malerczyk C; Freuling C; Gniel D; Giesen A; Selhorst T; Müller T Hum Vaccin Immunother; 2014; 10(10):2799-804. PubMed ID: 25483634 [TBL] [Abstract][Full Text] [Related]
6. Antibodies induced by vaccination with purified chick embryo cell culture vaccine (PCECV) cross-neutralize non-classical bat lyssavirus strains. Malerczyk C; Selhorst T; Tordo N; Moore S; Müller T Vaccine; 2009 Aug; 27(39):5320-5. PubMed ID: 19615958 [TBL] [Abstract][Full Text] [Related]
7. Occupational lyssavirus risks and post-vaccination monitoring. Brookes SM; Fooks AR Dev Biol (Basel); 2006; 125():165-73. PubMed ID: 16878474 [TBL] [Abstract][Full Text] [Related]
8. Favourable outcome in a patient bitten by a rabid bat infected with the European bat lyssavirus-1. Van Gucht S; Verlinde R; Colyn J; Vanderpas J; Vanhoof R; Roels S; Francart A; Brochier B; Suin V Acta Clin Belg; 2013; 68(1):54-8. PubMed ID: 23627196 [TBL] [Abstract][Full Text] [Related]
9. Utilisation of Chimeric Lyssaviruses to Assess Vaccine Protection against Highly Divergent Lyssaviruses. Evans JS; Wu G; Selden D; Buczkowski H; Thorne L; Fooks AR; Banyard AC Viruses; 2018 Mar; 10(3):. PubMed ID: 29543715 [TBL] [Abstract][Full Text] [Related]
10. Taiwan Bat Lyssavirus: In Vitro and In Vivo Assessment of the Ability of Rabies Vaccine-Derived Antibodies to Neutralise a Novel Lyssavirus. Shipley R; Wright E; Smith SP; Selden D; Fooks AR; Banyard AC Viruses; 2022 Dec; 14(12):. PubMed ID: 36560754 [TBL] [Abstract][Full Text] [Related]
11. Toward the Development of a Pan-Lyssavirus Vaccine. Ben Hamed S; Myers JF; Chandwani A; Wirblich C; Kurup D; Paran N; Schnell MJ Viruses; 2024 Jul; 16(7):. PubMed ID: 39066269 [TBL] [Abstract][Full Text] [Related]
12. Genetic and Antigenetic Characterization of the Novel Kotalahti Bat Lyssavirus (KBLV). Calvelage S; Tammiranta N; Nokireki T; Gadd T; Eggerbauer E; Zaeck LM; Potratz M; Wylezich C; Höper D; Müller T; Finke S; Freuling CM Viruses; 2021 Jan; 13(1):. PubMed ID: 33419096 [TBL] [Abstract][Full Text] [Related]
13. Isolation, antigenicity and immunogenicity of Lleida bat lyssavirus. Banyard AC; Selden D; Wu G; Thorne L; Jennings D; Marston D; Finke S; Freuling CM; Müller T; Echevarría JE; Fooks AR J Gen Virol; 2018 Dec; 99(12):1590-1599. PubMed ID: 29745870 [TBL] [Abstract][Full Text] [Related]
14. Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison. Wright E; Temperton NJ; Marston DA; McElhinney LM; Fooks AR; Weiss RA J Gen Virol; 2008 Sep; 89(Pt 9):2204-2213. PubMed ID: 18753230 [TBL] [Abstract][Full Text] [Related]
15. Cross-Neutralization Activities of Antibodies against 18 Lyssavirus Glycoproteins. Inoue Y; Kaku Y; Harada M; Ishijima K; Kuroda Y; Tatemoto K; Virhuez-Mendoza M; Nishino A; Yamamoto T; Inoue S; Matsuu A; Maeda K Jpn J Infect Dis; 2024 May; 77(3):169-173. PubMed ID: 38171846 [TBL] [Abstract][Full Text] [Related]
16. Current Rabies Vaccines Do Not Confer Protective Immunity against Divergent Lyssaviruses Circulating in Europe. Echevarría JE; Banyard AC; McElhinney LM; Fooks AR Viruses; 2019 Sep; 11(10):. PubMed ID: 31554170 [TBL] [Abstract][Full Text] [Related]
18. Protective activity of a murine monoclonal antibody against European bat lyssavirus 1 (EBL1) infection in mice. Montaño-Hirose JA; Lafage M; Weber P; Badrane H; Tordo N; Lafon M Vaccine; 1993 Sep; 11(12):1259-66. PubMed ID: 8256507 [TBL] [Abstract][Full Text] [Related]
19. Antigenic site changes in the rabies virus glycoprotein dictates functionality and neutralizing capability against divergent lyssaviruses. Evans JS; Selden D; Wu G; Wright E; Horton DL; Fooks AR; Banyard AC J Gen Virol; 2018 Feb; 99(2):169-180. PubMed ID: 29300155 [TBL] [Abstract][Full Text] [Related]
20. Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses. Brookes SM; Parsons G; Johnson N; McElhinney LM; Fooks AR Vaccine; 2005 Jul; 23(32):4101-9. PubMed ID: 15964478 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]